Maxim Group reiterated their buy rating on shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) in a report released on Wednesday. They currently have a $5.00 target price on the stock.

CYTX has been the subject of several other research reports. Zacks Investment Research raised shares of Cytori Therapeutics from a hold rating to a buy rating and set a $2.50 price target for the company in a research report on Monday, August 1st. Roth Capital reissued a buy rating and issued a $11.00 price target on shares of Cytori Therapeutics in a research report on Tuesday, June 28th.

Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at 2.08 on Wednesday. The company has a 50-day moving average price of $2.09 and a 200 day moving average price of $2.69. The company’s market capitalization is $42.62 million. Cytori Therapeutics has a one year low of $1.81 and a one year high of $6.45.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.04. Cytori Therapeutics had a negative return on equity of 210.47% and a negative net margin of 203.79%. The business earned $1.10 million during the quarter, compared to analyst estimates of $2.50 million. During the same period last year, the company earned ($0.06) EPS. The business’s revenue for the quarter was down 31.3% on a year-over-year basis. On average, analysts forecast that Cytori Therapeutics will post ($1.29) EPS for the current fiscal year.

An institutional investor recently bought a new position in Cytori Therapeutics stock. Cambridge Associates LLC MA ADV purchased a new position in shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,000 shares of the company’s stock, valued at approximately $852,000. Cytori Therapeutics makes up 0.4% of Cambridge Associates LLC MA ADV’s holdings, making the stock its 19th largest position. Hedge funds and other institutional investors own 18.48% of the company’s stock.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

5 Day Chart for NASDAQ:CYTX

Receive News & Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.